SCHEMBL5451029

SCHEMBL5451029

CN1CCN(c2ccc(N)c3ncccc23)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
GAA P10253 2/20 0.52
USP2 O75604 1/20 0.52
LMNA P02545 1/20 0.52
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HRH4 Q9H3N8 3/20 0.50
ADRA2C P18825 1/20 0.49
MAPT P10636 2/20 0.46
ALDH1A1 P00352 2/20 0.46
APAF1 O14727 1/20 0.46
TDP2 O95551 1/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
NCF1 P14598 1/20 0.46
KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3618930 0.88 HSP90AA1 (0.51) MEN1KMT2AGAAUSP2LMNA
SCHEMBL18434742 0.85 MAPT (0.53) MEN1KMT2AGAAUSP2LMNA
SCHEMBL7327580 0.82 ALDH1A1 (0.56) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL29509033 0.78 ADRA2C (0.62) KMT2AGAAHRH4ADRA2CMAPT
SCHEMBL3623865 0.78 ADRA2C (0.62) KMT2AGAAHRH4ADRA2CMAPT
SCHEMBL15161267 0.78 SMN1; SMN2 (0.56) MEN1KMT2AGAAUSP2LMNA
SCHEMBL25403430 0.78 POLB (0.51) LMNASMN1; SMN2MAPTALDH1A1POLB
SCHEMBL31121077 0.78 POLB (0.51) LMNASMN1; SMN2MAPTALDH1A1POLB
SCHEMBL5449804 0.77 ALDH1A1 (0.67) MEN1KMT2AUSP2LMNASMN1; SMN2
SCHEMBL28311804 0.77 ADRA2C (0.53) GAAHRH4ADRA2CMAPTNCF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11529350-B2 Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof SUMITOMO PHARMA ONCOLOGY, INC. (US) 2022-12-20 US disclosed
US-20210000825-A1 Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof SUMITOMO PHARMA ONCOLOGY, INC. 2021-01-07 US disclosed
WO-2021003417-A1 TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) 2021-01-07 WO disclosed
US-20070254894-A1 Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation KANE JOHN L JR 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210000825-A1 Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof TNK1, TNNI3K, TYK2 MEN1 1981/4885KMT2A 2525/4885GAA 1092/4885
US-11529350-B2 Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof TNK1, TNNI3K, TYK2 MEN1 1981/4885KMT2A 2525/4885GAA 1092/4885
US-20070254894-A1 Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation MKI67, VEGFA, KDR MEN1 3575/4885KMT2A 4653/4885GAA 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.